Impax to co-promote Wyeth's Pristiq

Impax Laboratories says that, beginning July 1, the firm's specialty brand products division will co-promote Wyeth's Pristiq  (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a  treatment for adult patients with major depressive disorder. Impax  Pharmaceuticals will utilize its 66 neurology-focused sales force to  promote he product.

Impax Labs entered into a three-year co-promotion agreement with Wyeth  in July 2008 to detail a product then to-be named by the drug major for  neurologists. Impax will receive a fee for each detail delivered. Other  terms of this agreement are confidential and were not disclosed.

Wyeth is in the process of being acquired by US pharmaceutical leviathan  Pfizer for $68.0 billion (Marketletter February 2).